Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma: a Controlled,Multicentre,Randomised, Phase 3 Trial
Phase of Trial: Phase II/III
Latest Information Update: 30 Mar 2017
At a glance
- Drugs Donafenib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Sponsors Suzhou Zelgen Biopharmaceuticals
- 21 Mar 2017 Planned number of patients changed from 600 to 660.
- 12 Aug 2016 Planned primary completion date changed from 1 Dec 2018 to 1 Feb 2019.
- 24 Mar 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.